Ligand backs Zerion's Dispersome drug-solubility tech in royalty and equity deal
What's the deal? Copenhagen-based Zerion Pharma has closed a combined royalty financing and equity investment with US-listed Ligand PharmaceuticalsDealroom has a profile for this one. Try Dealroom →.
Ligand invested an undisclosed amount to advance Zerion's Dispersome technology, which improves the solubility and bioavailability of small drug molecules. In return, it gains an equity stake and a share of future royalties.
The funding will also support Zerion's push to win regulatory approval for the first products using the technology.
Why now? Poor solubility limits 70-90% of novel drugs, making it a costly bottleneck for the industry.
Zerion's platform uses the protein beta-lactoglobulin as a carrier to turn poorly soluble compounds into stable, high-load formulations. It claims this can cut drug dosage by up to 75%, ease the tablet burden on patients, and reduce toxic waste.
"This is a major recognition of the potential of our Dispersome technology," said chief executive officer Ole WiborgDealroom has a profile for this one. Try Dealroom →. He added that Ligand's experience in drug formulation and licensing made it an ideal partner.
What could go wrong? The first products using the technology still need regulatory approval, leaving Ligand's royalty returns tied to clinical and commercial success.
That risk sits at the heart of the model. Royalty aggregators fund late-stage programs in exchange for long-term economic interests — bets that pay off only if the science clears the bar.
The signal: As a corporate royalty aggregator, Ligand's move into Zerion shows how royalty financing is expanding beyond individual drugs into the platforms that make them work. For technology developers, it offers capital without the dilution of a traditional raise — and a validating partner with deep formulation and licensing expertise.
Image credit: Generated with Gemini
Read more: MarketScreener
